US FDA approves Takeda, Protagonist's drug for rare blood cancer
28/08/2026 22:37
US FDA approves Takeda, Protagonist's drug for rare blood cancer Aug 28 (Reuters) - The U.S. Food and Drug Administration has approved a first-of-its-kind drug from Takeda Pharmaceutical 4502.T and Protagonist Therapeutics PTGX.O to treat a rare blood cancer, the health regulator said on Friday.
(Reporting by Kamal Choudhury, Mariam Sunny and Christy Santhosh in Bengaluru; Editing by Vijay Kishore)
Recent news on Takeda Pharmaceutical
See all newsTakeda launches sleep disorder pill in the US after DEA clearance removes final hurdle (updated)
Brief: Takeda's Orzeyful Available In U.S. By Prescription To Treat Narcolepsy Type 1 In Adults
Takeda launches sleep disorder pill in the US after DEA clearance removes final hurdle
Takeda Pharmaceutical Company Limited reports results for the quarter ended September 30 - Earnings Summary
Table: Takeda Pharmaceutical Company Limited -6-MTH group results (IFRS)